Tracheostomy and Dysphagia: True, True, and Unrelated?

2014 ◽  
Vol 23 (3) ◽  
pp. 116-122
Author(s):  
David Francis ◽  
Alexander Gelbard

The relationship between tracheostomy and dysphagia remains controversial. Many centers require swallow evaluations for all patients after tracheostomy because of the assumed increased rate of dysphagia and aspiration that they are thought to promote. Tracheostomies are now most commonly placed in the intensive care setting in adult patients with polytrauma or severe medical illness who are on mechanical ventilation. While tracheostomy and dysphagia often coexist in this population, they may not be directly related, as physiologic alterations observed in tracheostomized patients have not demonstrably translated into clinically significant complications of dysphagia. Instead, there is growing evidence that chronicity and severity of underlying illness, comorbidities, and recent intubation are the major arbiters of dysphagia in patient population. This brief report reviews the literature investigating the association between tracheostomy and dysphagia in adults, and discusses the role that illness severity, comorbidity, and intubation play in dysphagia etiology and how they confound the tracheostomy-dysphagia relationship.

2018 ◽  
Vol 31 (11) ◽  
pp. 691
Author(s):  
Paula Neves ◽  
Jorcélio Vicente ◽  
Heidy Cabrera ◽  
Iurie Pantazi

Botulism is a serious illness caused by exposure to botulinum toxin. It is manifested by flaccid, paralysis, symmetric and in descending pattern affecting cranial and peripheral nerves. Given the frequent need for invasive mechanical ventilation, these patients should be approached in an intensive care setting. Treatment with anti-botulinum toxin is the only effective treatment. The authors present the case of a 64-year-old patient, with vomiting and vertigo, evolution to diplopia, dysphagia and flaccid, muscle paralysis, installation after ingestion of canning homemade. From the etiologica, we highlight the electroneuromyogram study with a pre-synaptic lesion compatible with the botulism hypothesis. Progressive improvement of the deficits after administration of anti-botulinum toxin. A brief theoretical review is made of a serious, potentially fatal and infrequent pathology in our country.


2021 ◽  
pp. 00318-2021
Author(s):  
Dominic L Sykes ◽  
Michael G Crooks ◽  
Khaing Thu Thu ◽  
Oliver I Brown ◽  
Theodore J p Tyrer ◽  
...  

BackgroundContinuous Positive Airway Pressure (CPAP) and High Flow Nasal Oxygen (HFNO) have been used to manage hypoxaemic respiratory failure secondary to COVID-19 pneumonia. Limited data are available for patients treated with non-invasive respiratory support outside of the intensive care setting.MethodsIn this single-centre observational study we observed the characteristics, physiological observations, laboratory tests, and outcomes of all consecutive patients with COVID-19 pneumonia between April 2020 and March 2021 treated with non-invasive respiratory support outside of the intensive care setting.ResultsWe report the outcomes of 140 patients (Mean Age=71.2 [sd=11.1], 65% Male [n=91]) treated with CPAP/HFNO outside of the intensive care setting. Overall mortality was 59% and was higher in those deemed unsuitable for mechanical ventilation (72%). The mean age of survivors was significantly lower than those who died (66.1 versus 74.4 years, p<0.001). Those who survived their admission also had a significantly lower median Clinical Frailty Score than the non-survivor group (2 versus 4, p<0.001). We report no significant difference in mortality between those treated with CPAP (n=92, mortality: 60%) or HFNO (n=48, mortality: 56%). Treatment was well tolerated in 86% of patients receiving either CPAP or HFNO.ConclusionsCPAP and HFNO delivered outside of the intensive care setting are viable treatment options for patients with hypoxaemic respiratory failure secondary to COVID-19 pneumonia, including those considered unsuitable for invasive mechanical ventilation. This provides an opportunity to safeguard intensive care capacity for COVID-19 patients requiring invasive mechanical ventilation.


2010 ◽  
Vol 15 (1) ◽  
pp. 17-29
Author(s):  
Marcia L. Buck

OBJECTIVE Dexmedetomidine was approved by the Food and Drug Administration in 1999 for the sedation of adults receiving mechanical ventilation in an intensive care setting. It provides sedation with minimal effects on respiratory function and may be used prior to, during, and following extubation. Based on its efficacy in adults, dexmedetomidine is now being explored as an alternative or adjunct to benzodiazepines and opioids in the pediatric intensive care setting. This review describes the studies evaluating the safety and efficacy dexmedetomidine in infants and children and provides recommendations on dosing and monitoring. METHODS The MEDLINE (1950–November 2009) database was searched for pertinent abstracts, using the key term dexmedetomidine. Additional references were obtained from the bibliographies of the articles reviewed and the manufacturer. All available English-language case reports, clinical trials, retrospective studies, and review articles were evaluated. RESULTS Over two dozen case series and clinical studies have documented the utility of dexmedetomidine as a sedative in children requiring mechanical ventilation or procedural sedation. In several papers, dexmedetomidine use resulted in a reduction in the dose or discontinuation of other sedative agents. It may be of particular benefit in children with neurologic impairment or in those who do not tolerate benzodiazepines. The most frequent adverse effects reported with dexmedetomidine have been hypotension and bradycardia, in 10% to 20% of patients. These effects typically resolve with dose reduction. CONCLUSIONS Dexmedetomidine offers an additional choice for the sedation of children receiving mechanical ventilation in the intensive care setting or requiring procedural sedation. While dexmedetomidine is well tolerated when used at recommended doses, it has the potential to cause hypotension and bradycardia and requires close monitoring. In addition to clinical trials currently underway, larger controlled studies are needed to further define the role of dexmedetomidine in pediatric intensive care.


Author(s):  
Ivan Cabrilo ◽  
Claudia L. Craven ◽  
Hazem Abuhusain ◽  
Laura Pradini-Santos ◽  
Hasan Asif ◽  
...  

2015 ◽  
Vol 141 (9) ◽  
pp. 1645-1651 ◽  
Author(s):  
Christoph Sippel ◽  
Young Kim ◽  
Anja Wallau ◽  
Peter Brossart ◽  
Ingo Schmidt-Wolf ◽  
...  

2018 ◽  
Vol 46 (1) ◽  
pp. 167-167
Author(s):  
Danielle Aronowitz ◽  
Candace Smith ◽  
James Maurer ◽  
Jeffrey Nicastro ◽  
Vihas Patel ◽  
...  

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Juri Katchanov ◽  
Benno Kreuels ◽  
Florian P. Maurer ◽  
Kai Wöstmann ◽  
Johannes Jochum ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document